<DOC>
	<DOCNO>NCT00612859</DOCNO>
	<brief_summary>Preclinical clinical finding indicate LEV anxiolytic potential . There reason believe compound anxiolytic activity may broad clinical utility across anxiety spectrum . This trial intend explore LEV 's utility adult social anxiety disorder .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Levetiracetam Treatment Social Anxiety Disorder ( Generalized Type )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male female outpatient 18 70 year old inclusive ; symptom social anxiety disorder ( generalize type ) present least 1 year prior Selection Visit ; score &gt; =60 LSAS Selection Visit Randomization Visit . Additionally , clinician 's gloal impression change score must &gt; = 2 Randomization Visit ; telephone could directly contact . History autism Asperger 's Disease ; another primary axis I disorder fulfil diagnostic statistical manual mental disorders4th edition ( DSMIV ) criteria 6 month prior Screening ; major depression measure Hamilton Depression Rating Scale ( HAMD17 item ) total score &gt; 17 and/or suicide subscale score HAMD17 item &gt; 2 Selection Randomization Visit ; history electroconvulsive therapy within prior 3 month ; history psychotherapy stable ongoing least 6 month prior Visit 1 ; clinical history significantly impair renal function estimate creatinine clearance 80 mL/min ; clinically significant medical condition ; history clinically significant allergic condition allergy LEV pyrrolidone derivative ; neutrophil count less 1800/ÂµL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levetiracetam</keyword>
	<keyword>Keppra</keyword>
</DOC>